Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.65 AUD
Change Today -0.06 / -8.45%
Volume 171.7K
VLA On Other Exchanges
As of 11:51 PM 11/26/15 All times are local (Market data is delayed by at least 15 minutes).

viralytics ltd (VLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/9/15 - A$0.93
52 Week Low
12/22/14 - A$0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIRALYTICS LTD (VLA)

Related News

No related news articles were found.

viralytics ltd (VLA) Related Businessweek News

No Related Businessweek News Found

viralytics ltd (VLA) Details

Viralytics Limited, a biotechnology company, engages in developing oncolytic immunotherapy treatments for a range of cancers in Australia. Its lead investigational product is CAVATAK, a proprietary formulation of the common cold Coxsackievirus Type A21 that is in Phase II clinical trial for the treatment of late-stage melanoma; Phase ½ multi-dose intravenous clinical trial for late-stage melanoma, non-small cell lung, bladder, and prostate cancer; Phase I clinical trial for non-muscle invasive bladder cancer; and Phase Ib combination clinical trial for late-stage melanoma. The company is also conducting various preclinical programs on CAVATAK for the treatment of breast, multiple myeloma, pancreatic, and malignant glioma cancer, as well as for acute myeloid leukemia and chronic lymphocytic leukemia. In addition, it develops EVATAK to treat ovarian, prostate, and gastric cancer. The company has clinical trial collaboration agreement with Merck & Co., Inc. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

viralytics ltd (VLA) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$445.5K
Chief Financial Officer
Total Annual Compensation: A$150.8K
Director of Regulatory Affairs
Total Annual Compensation: A$29.3K
Compensation as of Fiscal Year 2015.

viralytics ltd (VLA) Key Developments

Viralytics and Merck & Co., Inc. to Collaborate on Combination Clinical Trial of CAVATAK and KEYTRUDA in Lung and Bladder Cancer

Viralytics Limited announced that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co. Inc. to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy. The Phase 1b clinical trial will evaluate the safety and efficacy of this novel immunotherapy combination in patients with either advanced stage non-small cell lung cancer (NSCLC) or metastatic bladder cancer. Viralytics, in collaboration with MSD, will be the sponsor of the study, which is planned to begin in 2016. As members of a new class of cancer treatments known as immunotherapies, both CAVATAK and KEYTRUDA are designed to enhance the body's own defences in fighting cancer. CAVATAK is an investigational agent based on a proprietary bioselected common cold virus that has been shown to preferentially infect and attack cancer cells. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, and may affect both tumour cells and healthy cells. The phase 1b combination trial will be the second stage of Viralytics' ongoing STORM clinical trial. The first stage of this study is focusing on assessing the intravenous administration of CAVATAK as a monotherapy in late-stage solid cancer patients. Initial results indicate that multiple intravenous infusions of CAVATAK have been well tolerated and have produced potential tumour viral replication in some advanced cancer patients, with anti-tumour activity seen in some individual lesions. The second stage of the STORM trial has been re-designed to assess the intravenous delivery of CAVATAK in combination with KEYTRUDA in patients with advanced NSCLC or metastatic bladder cancer. The trial will be an open-label, multi-centre study with dose escalation of CAVATAK in combination with fixed doses of KEYTRUDA, followed by an expansion cohort phase. The final cohort will contain approximately 80 patients, across both indications. The aim of the study is to establish a recommended dose regimen for the CAVATAK/KEYTRUDA combination and to evaluate anti-cancer activity and patient tolerability. Patient biopsies will be assessed for changes in the tumour microenvironment that may provide a further signal of activity. Viralytics will provide CAVATAK and sponsor the study; MSD will provide KEYTRUDA and conduct biomarker analysis. The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial. Additional details of the collaboration were not disclosed.

Viralytics Limited, Annual General Meeting, Nov 18, 2015

Viralytics Limited, Annual General Meeting, Nov 18, 2015. Location: McCullough Robertson. Agenda: To receive and consider the financial report, the directors' report and the independent audit report of the company for the financial year ended 30 June 2015; to consider the re-election of Dr. Leonard Post; to consider remuneration report; and to consider the issue of options to Dr. Malcolm McColl; to consider the issue of options to Mr. Paul Hopper; to consider the issue of options to Dr. Leonard Post; to consider the issue of options to Mr. Peter Turvey; to consider additional share capacity; and to consider the proportional takeover approval provisions.

Viralytics Limited Announces Earnings Results for the Year Ended June 30, 2015

Viralytics Limited announced earnings results for the year ended June 30, 2015. The company reported net cash used in operating activities for the year was $4.5 million, cash position at the end of the year was $21.6 million and reported loss was $4.3 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:AU A$0.65 AUD -0.06

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.5x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VIRALYTICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at